EPIDEMIOLOGY AND PUBLIC POLICY: THE ROLE OF THE INTERNATIONAL JOINT POLICY COMMITTEE OF THE SOCIETIES OF EPIDEMIOLOGY (IJPC-SE)

Similar documents
Innovation in HTA: What is the additional value?

Translational scientist competency profile

Draft for consideration

SMA Europe Code of Practice on Relationships with the Pharmaceutical Industry

THE UNIVERSITY OF AUCKLAND INTELLECTUAL PROPERTY CREATED BY STAFF AND STUDENTS POLICY Organisation & Governance

Alison N. Davis. Focus Areas. Overview

POLICY PHILOSOPHY DEFINITIONS AC.2.11 INTELLECTUAL PROPERTY. Programs and Curriculum. APPROVED: Chair, on Behalf of SAIT s Board of Governors

INAHTA Working Group Ethical Issues in HTA

Taking a Deep Breath in a Busy World

KKR Credit Advisors (Ireland) Unlimited Company PILLAR 3 DISCLOSURES

Building quality into HTA and Coverage Decision- Making Processes: What are the features of good practice in HTA?

POLICY ON INVENTIONS AND SOFTWARE

The Assessment of Benefits and Harms and Their Relative Importance for Patients, Industry and Agencies: How should they be captured?

Priorities for medical research in the UK

Recommendations of the Microgravity Review Panel

Advances and Perspectives in Health Information Standards

Your guide to Inquests

13 December A NERA Briefing: Expert Workshop on HTA Workshop Sponsored by Pfizer

December Eucomed HTA Position Paper UK support from ABHI

DISPOSITION POLICY. This Policy was approved by the Board of Trustees on March 14, 2017.

CCG Improvement and Assessment Framework 2016/17. Briefing Document

An Essential Health and Biomedical R&D Treaty

Inter and Transdisciplinarity in Social Sciences. Approaches and lessons learned

The creation of the Emergency Preparedness and Response Expert Group (EPREG) which held its second meeting last month.

WORKSHOP ON BASIC RESEARCH: POLICY RELEVANT DEFINITIONS AND MEASUREMENT ISSUES PAPER. Holmenkollen Park Hotel, Oslo, Norway October 2001

TECHNOLOGICAL FORECASTING

UW REGULATION Patents and Copyrights

Virtual Clinical Trials: Challenges and Opportunities

JOB DESCRIPTION. Department: Technical Length of contract: 3 years renewable. Reporting to: Chief of Party Direct reports: Numbers to be confirmed

Bennett Jones. John N. Craig Q.C. Partner, Co-Head of Construction. Your lawyer. Your law firm. Your business advisor.

NEWS RELEASE. Life sciences companies tout their expertise in India

Dear Secretary of State Parreira, Dear President Aires-Barros, Dear ALLEA delegates, esteemed faculty of today s workshop,

Australian Census 2016 and Privacy Impact Assessment (PIA)

Infrastructure Funding Panel

Policy Partnership on Science, Technology and Innovation Strategic Plan ( ) (Endorsed)

What Makes International Research Ethical (Or Unethical)? Eric M. Meslin, Ph.D Indiana University Center for Bioethics

Horizon Scanning. Why & how to launch it in Lithuania? Prof. Dr. Rafael Popper

UNLOCKING THE VALUE OF SASB STANDARDS

INGSA South East Asia Government Science Advice workshop. Workshop Report

November 6, Keynote Speaker. Panelists. Heng Xu Penn State. Rebecca Wang Lehigh University. Eric P. S. Baumer Lehigh University

HTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:

So You Want to be An Expert?:

[Definitions of terms that are underlined are found at the end of this document.]

Intellectual Property

Fact Sheet IP specificities in research for the benefit of SMEs

EP Interest Group Mental Health, Brussels 22/09/11 Tinne Vandensande King Baudouin Foundation

25 th Workshop of the EURORDIS Round Table of Companies (ERTC)

Parenteral Nutrition Down Under Inc. (PNDU) Working with Pharmaceutical Companies Policy (Policy)

Tuning-CALOHEE Assessment Frameworks for the Subject Area of CIVIL ENGINEERING The Tuning-CALOHEE Assessment Frameworks for Civil Engineering offers

EDUCATION. B.S. Brigham Young University, Provo, UT, cum laude (2001) Major, Accounting RESEARCH INTERESTS

Travel to Winnipeg to attend U15 Provost's/Vice-President. $1, (Research) (VPR) meeting. 2.

National Workshop on Responsible Research & Innovation in Australia 7 February 2017, Canberra

ESF Exploratory Workshop "The future of research in sport participation in the lifespan"

Triennial Review of the Medicines and Healthcare Products Regulatory Agency. Call for Evidence

SAE International Engineering. Advanced.

SATELLITE NETWORK NOTIFICATION AND COORDINATION REGULATIONS 2007 BR 94/2007

Guide to getting a Lasting Power of Attorney

Why behavioural economics is essential for the success of the implementation of a wearable or health app. Behavioural Research Unit

General Manager Assurance and Risk Management in Oakton;

In 2005 His Honour Humphrey LLoyd returned to being an arbitrator in international and domestic matters.

Discovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.

Course Outline and Syllabus for Students

IBC UK Conferences and Matrix Chambers bring you the second annual masterclass - Privacy. and the Media

Privacy Policy SOP-031

April By Type of Approach- Transfemoral and Transapical. By Region- North America, Europe, APAC and RoW

IP and Technology Management for Universities

MINISTRY OF HEALTH STAGE PROBITY REPORT. 26 July 2016

WILLIAM H. GRONER TEACHING-PUBLIC SPEAKING

IHRA-ITS: Recent Developments of the European Statement of Principles on HMI

Loyola University Maryland Provisional Policies and Procedures for Intellectual Property, Copyrights, and Patents

EL PASO COMMUNITY COLLEGE PROCEDURE


Alberta Health Services and Advancing Uptake of HTA & Innovation

Whole of Society Conflict Prevention and Peacebuilding

UCF Patents, Trademarks and Trade Secrets. (1) General. (a) This regulation is applicable to all University Personnel (as defined in section

EU Research Integrity Initiative

The European statement of principles on human machine interaction 2005

Transportation Education in the New Millennium

ANNUAL CONFERENCE 2014

CRS Report for Congress

Overview on Medicines Regulation: regulatory cooperation and harmonization in focus

Applicant PIN + Family name on top of each page Partnership Workshops Program Proposal: Sustainable Energy Futures for Halifax

Maximizing Innovation Funding for Technology Development. MNP SR&ED Team. Presented by: Date:

Heaven and hell: visions for pervasive adaptation

Remote, Connected and Savvy! June 2017

Disclosure Initiative Principles of Disclosure

Scottish Health and Life Sciences Innovation Workshop. The Industrial Strategy Challenge Fund

Draft Report of the 1 st Session GRSG informal group on awareness of Vulnerable Road Users proximity in low speed manoeuvres (VRU-Proxi)

The CNSC s Approach to Communications

Lambeth Clinical Commissioning Group

TECHNOLOGY INNOVATION LEGISLATION HIGHLIGHTS

SHTG primary submission process

Welcome! You are reading ChangeAbility, a newsletter published by Business Coach Urs Koenig PhD, MBA.

Emerging Drinking Water Contaminants

Getting the Most From Your IP Budget: Strategies for IP Portfolio Management and Litigation Avoidance

Web seminars make events more accessible to people as you avoid the time and cost involved in travelling to an event.

Attorney Business Plan. Sample 3

IE Courses and Options

Daniel E. Turner. Focus Areas. Overview

Diana Gordick, Ph.D. 150 E Ponce de Leon, Suite 350 Decatur, GA Health Insurance Portability and Accountability Act (HIPAA)

Transcription:

EPIDEMIOLOGY AND PUBLIC POLICY: THE ROLE OF THE INTERNATIONAL JOINT POLICY COMMITTEE OF THE SOCIETIES OF EPIDEMIOLOGY (IJPC-SE) MARK OREMUS, PHD COLIN L. SOSKOLNE, PHD CANADIAN SOCIETY FOR EPIDEMIOLOGY & BIOSTATISTICS (CSEB) BIENNIAL CONFERENCE PARADIGMS TO PRAGMATISM: EPIDEMIOLOGY AND BIOSTATISTICS FOR THE CHANGING WORLD JUNE 1-4, 2015 HILTON MEADOWVALE HOTEL, MISSISSAUGA, ON 1

ACKNOWLEDGMENT AND DISCLOSURE As an IJPC-SE member society, the CSEB created space in the programme for this lunch workshop and waived the registration fee for both speakers. Neither speaker has a financial conflict-ofinterest to declare. 2

LUNCH WORKSHOP Story about the IJPC-SE Backgrounder: epidemiology and policy Influence, integrity and vigilance Small-group exercise, with a rapporteur for each group to permit discussion 3

IJPC-SE AND ITS MISSION: Volunteer-driven, not-for-profit consortium, currently comprising 19 national and international memberprofessional societies/associations Impartially generate, report and apply epidemiological methods to the formulation, implementation and evaluation of evidence for use in informing health policy 4

IJPC-SE GOAL & APPROACH Goal is to serve the public interest by informing health policy and related areas of endeavour through its work at the nexus of research and policy Coordinates inter-professional society activities that are related to research and practice in the generation of evidence, as well as in evidence-based policy application, formulation, implementation and evaluation Promotes epidemiological best practices to inform policy 5

IJPC-SE BRIEF HISTORY Formed in Seattle in 2006 at the 2 nd North American Congress of Epidemiology It is now in its 9 th year of operation 1 st Chair: Roberta Ness (2006-2007) 2 nd Chair: Susan Sacks (2008-2009) 3 rd Chair: Stanley H. Weiss (2010-2013) 4 th Chair: Colin L. Soskolne (2014-2015) Chair-Elect: Wael Al-Delaimy (2016 -?) Website, Founding Bylaws, related policy documents, and Not-for-Profit status set in motion in 2012-2015 A major initiative was the launch in 2012 of its Position Statement on Asbestos 6

EPIDEMIOLOGY (1) the study of the occurrence and distribution of health-related states or events in specified populations, including the study of the determinants influencing such states; and (2) the application of this knowledge to control health problems Epidemiologists have become methodologists Go-to people to design high-quality studies Traditional view: epidemiologists must conduct objective research, publish the results, and leave policy to others 7

EVIDENCE-BASED PRACTICE Historically, medical decisions were based on expert opinion, clinical experience, and authoritarian judgment Research evidence (often poor quality until the latter part of 20th Century) was not an influential driver of medical practice Research did not have much influence on policy either 8

EVIDENCE-BASED PRACTICE Late 1960s 1990s: development of evidence-based practice (EBP): use highquality research to inform/guide clinical practice Clinical epidemiologists became the leading practitioners of EBP EBP led to tremendous advances in research methods (studies had to be high quality to provide useful evidence) 9

POLICY 1990s present: high cost of health care has prompted policy makers to mandate assessments of the evidence for treatment efficacy and effectiveness before reimbursing new therapies AB, ON, QC: leaders in evidence-based reimbursement decisions NICE in UK: evaluates new health technologies and makes reimbursement recommendations to NHS Public health: epidemiologic evidence is used to inform health policy 10

CELLPHONES AND DRIVING Redelmeier and Tibshirani, NEJM, 1997: Case-crossover study of cellular telephone use (exposure) and motor vehicle accidents (outcome) in Toronto Odds of a motor vehicle accident were 4.6 times greater in persons who used cellular telephones while driving, compared to persons who did not use cellphones while driving 11

EVIDENCE THAT CONTRIBUTED TO THE BAN ON CELLPHONE USE WHILE DRIVING 12

PART 2: WORKSHOP PRESENTATION Colin L. Soskolne, PhD www.colinsoskolne.com Professor emeritus, University of Alberta, Canada Adjunct Professor, University of Canberra, Australia Chair, International Joint Policy Committee of the Societies of Epidemiology (IJPC-SE) 13

IN WHOSE BEST INTERESTS? Public interest vs any other interest(s)? In whose best interests do epidemiologists work? Is there any allowance for variation in this view? In whose best interest is research done? Is every research question framed to serve one interest or another? Whose interests are being served when research is funded by public funds? And, whose best interests are being served when research is funded by private/corporate dollars? Are both appropriate? Is there any moral tension in choosing a public over a private/corporate source of funds to address a particular scientific question? 14

PROFESSIONAL INTEGRITY / ETHICS / MORALITY / LAW: The defining influences in our behaviour / conduct as people and as research scientists in the social context in which we live, work and play 15

HUMAN AND SYSTEM FRAILTIES Junk science: Our professional obligation to be vigilant and especially careful in peer review Need for oversight (as in Human Research Ethics Boards/IRBs) The need to keep ourselves on track with ETHICS GUIDELINES and related activities 16

RELENTLESS PRESSURE FROM VESTED INTERESTS Manoeuver their way onto review panels, influence Boards of our professional associations, and infiltrate the literature with junk science Expert witness tensions arise between the plaintiff and defence sides of the argument in tort actions where the rubber hits the road concerning policy decisions David vs Goliath? Current major initiative of the IJPC-SE is its Working Group on Conflict-of-Interest and Disclosure 17

ONE FORCE INFLUENCING ACADEMIC PERFORMANCE Differing Journal policies exist on the mention of policy-related implications of any research paper s findings A TENSION ARISES BETWEEN THE NEED, ON THE ONE HAND, FOR ARMS-LENGTH SCHOLARLY ENDEAVOUR AND, ON THE OTHER HAND, THE NEED FOR COMMUNITY ENGAGEMENT 18

WORKSHOP EXERCISE AND ITS CONTEXT In small groups, consider the scenario in which you are working as an associate professor of epidemiology in a highly-regarded Canadian university Your recent promotion to associate professor was based on your contribution as a research scientist to better explicating the relationship between exposure X and disease Y (and now for which you are a recognized expert), to your good teaching record, and to your professional service on both University-wide and community committees/advisory boards 19

WORKSHOP EXERCISE: THE CHALLENGE/OFFER You are approached by a law firm to accept a 3- year contract in the form of a retainer. The law firm usually works in support of corporate interests against people claiming harm from their products. The lawyers want you to conduct, for a large amount of money that will be paid to your university for your use in research, a large study to further explore the relationship between exposure X and disease Y The law firm requires that: (a) your study design must exclude certain categories of exposed people; and (b) the law firm will have a veto right over your final paper for publication 20

WORKSHOP EXERCISE: YOUR APPROACH TO A DECISION Do you accept the contract, or not? What is your rationale for either decision? What protections do you assume should be in place? Other? 21

WORKSHOP EXERCISE: OVERVIEW In small groups, consider the scenario in which you are working as an associate professor of epidemiology in a highly regarded Canadian university. Your recent promotion to associate professor was based on your contribution as a research scientist to better explicating the relationship between exposure X and disease Y (and now for which you are a recognized expert), to your good teaching record, and to your professional service on both University-wide and community committees/advisory boards. You are approached by a law firm to accept a 3-year contract in the form of a retainer. The law firm usually works in support of corporate interests against people claiming harm from their products. The lawyers want you to conduct, for a large amount of money that will be paid to your university for your use in research, a large study to further explore the relationship between exposure X and disease Y. The law firm requires that: (a) your study design must exclude certain categories of exposed people; and (b) the law firm will have a final veto right over your final paper for publication. Do you accept the contract, or not? What is your rationale for either decision? What protections do you assume should be in place? Other? 22

THANK YOU FOR CONTRIBUTING TO OUR COLLECTIVE WORKSHOP EXPERIENCE! www.ijpc-se.org 23